637 related articles for article (PubMed ID: 27687306)
21. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
[TBL] [Abstract][Full Text] [Related]
22. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.
Mansuet-Lupo A; Alifano M; Pécuchet N; Biton J; Becht E; Goc J; Germain C; Ouakrim H; Régnard JF; Cremer I; Laurent-Puig P; Dieu-Nosjean MC; Blons H; Damotte D
Am J Respir Crit Care Med; 2016 Dec; 194(11):1403-1412. PubMed ID: 27299180
[TBL] [Abstract][Full Text] [Related]
24. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
25. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.
Takada K; Okamoto T; Tominaga M; Teraishi K; Akamine T; Takamori S; Katsura M; Toyokawa G; Shoji F; Okamoto M; Oda Y; Hoshino T; Maehara Y
PLoS One; 2017; 12(7):e0181598. PubMed ID: 28727766
[TBL] [Abstract][Full Text] [Related]
27. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
28. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
29. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
30. Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific.
Li X; Wei S; Deng L; Tao H; Liu M; Zhao Z; Du X; Li Y; Hou J
BMC Pulm Med; 2023 Mar; 23(1):99. PubMed ID: 36964522
[TBL] [Abstract][Full Text] [Related]
31. EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
Zhao Y; Pan Y; Cheng C; Zheng D; Zhang Y; Gao Z; Fu F; Li H; Zheng S; Zhuge L; Mao H; Kuang M; Tao X; Peng Y; Hu H; Xiang J; Li Y; Sun Y; Chen H
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1781-1789. PubMed ID: 32361787
[TBL] [Abstract][Full Text] [Related]
32. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Bria E; Pilotto S; Amato E; Fassan M; Novello S; Peretti U; Vavalà T; Kinspergher S; Righi L; Santo A; Brunelli M; Corbo V; Giglioli E; Sperduti I; Milella M; Chilosi M; Scarpa A; Tortora G
Oncotarget; 2015 May; 6(14):12783-95. PubMed ID: 25904052
[TBL] [Abstract][Full Text] [Related]
33. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
34. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
[TBL] [Abstract][Full Text] [Related]
36. Differences in Immunological Landscape between
Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
[TBL] [Abstract][Full Text] [Related]
37. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
38. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
40. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
